Fabry disease (FD) is a rare, progressive multisystemic disorder, caused by deficiency of the lysosomal enzyme alpha-galactosidase A.1,2 The current treatment options for FD include intravenous enzyme replacement therapy (ERT)3,4 and, more recently, an oral chaperone therapy.5 Here, GLA is linked to Fabry disease.